OMB

Regulatory Opinion: Year in Review

Regulatory Opinion: Year in Review

The REINS Act, the ozone standard, regulatory reform, cost-benefit analysis, the Affordable Care Act, and Dodd-Frank, and more … as discussed in our top opinion posts from 2011.

Regulatory Year in Review: 2011

Regulatory Year in Review: 2011

Cost-benefit analysis, Europe’s E. coli outbreak, health care antitrust, environmental regulation, and more … as discussed in our top analysis posts from 2011.

GAO Says Dodd-Frank Rulemaking Should be Improved

GAO Says Dodd-Frank Rulemaking Should be Improved

Financial regulation needs more rigorous analysis and better interagency communication.

Harvesting Clean Energy

Harvesting Clean Energy

New source performance standards should include energy efficiency.

CPR Report on OIRA’s Meetings Ignores Their Context

CPR Report on OIRA’s Meetings Ignores Their Context

Increased regulatory action under Obama means that OIRA has more regulations to review.

Agencies Should Pay For Any Copyrighted Materials They Incorporate by Reference

Agencies Should Pay For Any Copyrighted Materials They Incorporate by Reference

Incorporated materials may be difficult to obtain, so agencies must make them available at their own expense.

Senate Fails to Overturn the FCC’s Net Neutrality Rules

Senate Fails to Overturn the FCC’s Net Neutrality Rules

New “open Internet” regulations survive congressional challenge.

The Rise of Eurolegalism

The Rise of Eurolegalism

Europe is increasingly adopting its own form of adversarial legalism.

Activists Raise Concerns about Enforcement of UK Bribery Act

Activists Raise Concerns about Enforcement of UK Bribery Act

Initial conviction under new law may not stem criticisms of government enforcement policies.

Bipartisan Bill Would Add Procedural Hurdles to Agency Rulemaking

Bipartisan Bill Would Add Procedural Hurdles to Agency Rulemaking

Bill places special emphasis on rules with a high impact on the economy.

Getting the Numbers Right

Getting the Numbers Right

Judicial review of benefit-cost analysis is no cure-all.